Posted in:News Pfizer Challenges Genentech’s Carter ’213 Antibody Patent With Two New IPR Petitions By C. Nichole Gifford June 2, 2017 Comments are off On May 25, 2017, Pfizer, Inc. (“Pfizer”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent No. 6,407,213... Read more Tagged with: Celltrion, Genentech, Herceptin®, Hospira, IPR, Legal, Mylan, News, Pfizer, PTAB, Roche, Teva, trastuzumab, USPTO http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News FDA Advisory Committee Recommends Approval of Pfizer’s Proposed Biosimilar to Amgen’s Epogen®/Procrit® (epoetin alfa) By C. Nichole Gifford May 31, 2017 Comments are off Pfizer announced last week that the FDA’s Oncologic Drug Advisory Committee (ODAC) recommended its proposed biosimilar to Amgen’s... Read more Tagged with: Amgen, Amgen v. Hospira, BPCIA, epoetin alfa, Epogen®, FDA, Hospira, Janssen, News, Pfizer, Procrit®, Regulatory, Retacrit® http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Partner Nikki Gifford Presents at World Biosimilar Congress USA 2017 By C. Nichole Gifford May 26, 2017 Comments are off Partner Nikki Gifford gave a presentation entitled “Intellectual Property – Recent Developments and Implications,” at the World... Read more Tagged with: BPCIA, IPR, Litigation, Patent Dance, Sandoz v. Amgen, Supreme Court http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Celltrion Challenges Another Herceptin® Patent With Two New IPR Petitions By C. Nichole Gifford May 18, 2017 Comments are off Last week, Celltrion, Inc. (“Celltrion”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent No. 6,407,213... Read more Tagged with: Celltrion, Genentech, Herceptin®, IPR, Legal, News, PTAB, Roche, Teva, trastuzumab, USPTO http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Baxalta Files Patent Infringement Suit Against Genentech and Chugai Over Antibody for Hemophilia (Emicizumab) By C. Nichole Gifford May 12, 2017 Comments are off Baxalta Incorporated and Baxalta GmbH (collectively “Baxalta” or “Plaintiffs”) filed a Complaint in the United States District... Read more Tagged with: Baxalta, Chugai, District Court, emicizumab, Genentech, Legal, Litigation, Shire http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Pfizer Files IPR Petitions on Three More Rituximab® Patents By C. Nichole Gifford May 3, 2017 Comments are off Over the last two weeks, Pfizer, Inc. (“Pfizer”) has filed petitions for inter partes review (“IPR”) of three additional patents... Read more Tagged with: Biogen, Celltrion, Genentech, IPR, Legal, Mabthera, News, Pfizer, PTAB, Rituxan®, Rituximab, Roche, USPTO http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:News Celltrion Submits Application for Herzuma (trastuzumab) in Japan and Launches Truxima (rituximab) in Europe By C. Nichole Gifford May 2, 2017 Comments are off Celltrion announced last week that it has submitted an application for approval of Herzuma, its proposed trastuzumab biosimilar (CT-P6), in... Read more Tagged with: Celltrion, EMA, FDA, Genentech, Mabthera, News, Regulatory, Rituxan®, Rituximab, Roche http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus